Vir Biotechnology, Inc. (VIR): Cost of Revenue
$26.0K
Year ended 2025-12-31
$15.0K
Trailing 12 months to 2026-06-30
-94.4%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.0K | -96.9% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $845.0K | -69.4% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $2.77M | -98.1% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $146.32M | +122.1% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $65.86M | n/a | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $0 | n/a | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $0 | n/a | 2022-02-28, From 2019-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $26.0K | -96.9% |
| Compugen Ltd (CGEN) | 2025-12-31 | $9.25M | +16.7% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $70.95M | +56.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $96.37M | +746.3% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $30.90M | +8.8% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $26.99M | +11.0% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $753.0K | n/a |
| Agenus Inc (AGEN) | 2025-12-31 | $1.02M | +110.3% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $39.21M | -16.7% |
Compare VIR, CGEN, RXRX, AUTL side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗